Entecavir: stability and drug-excipient compatibility
Abstract Entecavir is an inhibitor of hepatitis B virus (HBV) DNA synthesis that has been widely prescribed in the treatment of chronic infections caused by the virus. Production of generic ETV drugs is an ongoing global endeavor, with particular significance for developing countries that rely on im...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2025-01-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100304&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592493594542080 |
|---|---|
| author | Ariadne Botto Fiorot Clayton Raynan dos Santos Thiago Padovani Xavier Taisa Shimosakai de Lira Marcelo Antonio de Oliveira |
| author_facet | Ariadne Botto Fiorot Clayton Raynan dos Santos Thiago Padovani Xavier Taisa Shimosakai de Lira Marcelo Antonio de Oliveira |
| author_sort | Ariadne Botto Fiorot |
| collection | DOAJ |
| description | Abstract Entecavir is an inhibitor of hepatitis B virus (HBV) DNA synthesis that has been widely prescribed in the treatment of chronic infections caused by the virus. Production of generic ETV drugs is an ongoing global endeavor, with particular significance for developing countries that rely on importing the expensive reference drug. ETV-excipient compatibility studies were conducted with the declared inputs in solid pharmaceutical formulations on the market through thermal analysis and HPLC techniques. Thermal analyses by TGA and DTA indicated compatibility of entecavir with the excipients microcrystalline cellulose, crospovidone, titanium dioxide, magnesium stearate, hypromellose, polyethylene glycol and povidone; this was confirmed via HPLC. Lactose monohydrate proved to be incompatible with ETV in thermal and chromatographic assays. The thermal analysis of marketed solid dosage forms revealed a predominance of the lactose monohydrate profile at the expense of ETV and other inputs in the TGA and DTA curves, due to its high content in the formulations; this makes the evidence of ETV-lactose chemical interaction even more important. Compatibility tests by HPLC showed no chemical interaction of ETV with the excipient mannitol, a soluble diluent proposed as a replacement for lactose monohydrate, with the same function in the formulation. |
| format | Article |
| id | doaj-art-519cc12222d244b884d65bd7cdc621ab |
| institution | Kabale University |
| issn | 2175-9790 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj-art-519cc12222d244b884d65bd7cdc621ab2025-01-21T07:41:20ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902025-01-016110.1590/s2175-97902025e23630Entecavir: stability and drug-excipient compatibilityAriadne Botto FiorotClayton Raynan dos SantosThiago Padovani XavierTaisa Shimosakai de LiraMarcelo Antonio de Oliveirahttps://orcid.org/0000-0002-7842-807XAbstract Entecavir is an inhibitor of hepatitis B virus (HBV) DNA synthesis that has been widely prescribed in the treatment of chronic infections caused by the virus. Production of generic ETV drugs is an ongoing global endeavor, with particular significance for developing countries that rely on importing the expensive reference drug. ETV-excipient compatibility studies were conducted with the declared inputs in solid pharmaceutical formulations on the market through thermal analysis and HPLC techniques. Thermal analyses by TGA and DTA indicated compatibility of entecavir with the excipients microcrystalline cellulose, crospovidone, titanium dioxide, magnesium stearate, hypromellose, polyethylene glycol and povidone; this was confirmed via HPLC. Lactose monohydrate proved to be incompatible with ETV in thermal and chromatographic assays. The thermal analysis of marketed solid dosage forms revealed a predominance of the lactose monohydrate profile at the expense of ETV and other inputs in the TGA and DTA curves, due to its high content in the formulations; this makes the evidence of ETV-lactose chemical interaction even more important. Compatibility tests by HPLC showed no chemical interaction of ETV with the excipient mannitol, a soluble diluent proposed as a replacement for lactose monohydrate, with the same function in the formulation.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100304&lng=en&tlng=enEntecavirStabilityDrug-excipient compatibilityThermal analysisHPLC |
| spellingShingle | Ariadne Botto Fiorot Clayton Raynan dos Santos Thiago Padovani Xavier Taisa Shimosakai de Lira Marcelo Antonio de Oliveira Entecavir: stability and drug-excipient compatibility Brazilian Journal of Pharmaceutical Sciences Entecavir Stability Drug-excipient compatibility Thermal analysis HPLC |
| title | Entecavir: stability and drug-excipient compatibility |
| title_full | Entecavir: stability and drug-excipient compatibility |
| title_fullStr | Entecavir: stability and drug-excipient compatibility |
| title_full_unstemmed | Entecavir: stability and drug-excipient compatibility |
| title_short | Entecavir: stability and drug-excipient compatibility |
| title_sort | entecavir stability and drug excipient compatibility |
| topic | Entecavir Stability Drug-excipient compatibility Thermal analysis HPLC |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502025000100304&lng=en&tlng=en |
| work_keys_str_mv | AT ariadnebottofiorot entecavirstabilityanddrugexcipientcompatibility AT claytonraynandossantos entecavirstabilityanddrugexcipientcompatibility AT thiagopadovanixavier entecavirstabilityanddrugexcipientcompatibility AT taisashimosakaidelira entecavirstabilityanddrugexcipientcompatibility AT marceloantoniodeoliveira entecavirstabilityanddrugexcipientcompatibility |